R-Pharm is planning to establish two research facilities in its Sputnik Technopolis factory premises by the end of 2023 for the advancement of biological and chemical formulations. Their main task is to develop original and import-substituting drugs for the treatment of socially significant diseases, according to the company’s website.
One of the centers will produce drugs obtained by chemical synthesis, the other will be engaged in the creation of monoclonal antibodies. “Our biotechnology center will utilize monoclonal antibodies for the treatment of oncological and autoimmune diseases and infections targeting specific pathogens,” stated Timofey Petrov, the General Director of the Sputnik Technopolis plant.
Earlier, R-Pharm agreed with Kazan Federal University on the creation of an innovative gene therapy drug for the treatment of spinal muscular atrophy. The drug’s cost is anticipated to be significantly lower than the price set by foreign manufacturers for their treatments of this rare condition.
